Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6092577 | Gastroenterology | 2016 | 37 Pages |
Abstract
In a randomized controlled trial, addition of simvastatin to standard therapy did not reduce rebleeding, but was associated with a survival benefit for patients with Child-Pugh class A or B cirrhosis. Survival was not the primary end point of the study, so these results require validation. The incidence of rhabdomyolysis in patients receiving 40 mg/d simvastatin was higher than expected. European Clinical Trial Database ID: EUDRACT 2009-016500-24; ClinicalTrials.gov ID: NCT01095185.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Juan G. Abraldes, Candid Villanueva, Carles Aracil, Juan Turnes, Manuel Hernandez-Guerra, Joan Genesca, Manuel Rodriguez, Jose Castellote, Juan Carlos GarcÃa-Pagán, Ferran Torres, Jose Luis Calleja, Agustin Albillos, Jaime Bosch,